Researchers developing new drug class to combat Alzheimer's

Oct 22, 2008

The University of Illinois at Chicago College of Pharmacy has received a four-year, $1.87 million grant from the National Institutes of Health to continue research into discovering a new drug class that will treat Alzheimer's disease.

Gregory Thatcher, professor of medicinal chemistry and pharmacognosy and the grant's principal investigator, and his former colleagues at Queen's University in Kingston, Ontario, proposed a dozen years ago that delivering nitric oxide to the brain would be beneficial in combating neurodegenerative diseases, since nitric oxide is a messenger molecule essential for learning and memory.

"But this wasn't a popular notion, because nitric oxide is a free radical gas and toxic at higher concentrations," Thatcher said. "But then again, so is oxygen, and it's also rather important for life. It's a question of understanding the chemistry and engineering the molecule to deliver nitric oxide bioactivity, but also additional activity to restore and protect brain function."

Alzheimer's disease is a devastating illness affecting one out of three people over the age of 80, and is the sixth leading cause of death in the United States, according to the Alzheimer's Association. There are currently no drugs to slow the rate of progression of the disease. "Even new drugs that effectively treat the symptoms would be of enormous benefit to patients and caregivers," Thatcher said.

Along with working on the new NIH grant, Thatcher and Pavel Petukhov, assistant professor of medicinal chemistry and pharmacognosy, are assisting Dr. Ottavio Arancio of Columbia University in studying how the inhibition of the enzyme calpain can be a therapeutic target for Alzheimer's. Arancio received a four-year, $2.1 million grant from the NIH for the study.

Arancio, who in turn is assisting Thatcher on his new research project, recently showed the importance of controlling nitric oxide signaling in restoring normal brain function in animal models of Alzheimer's.

Thatcher is also the beneficiary of a new five-year, $1.6 million NIH grant to study nitric oxide chimera drugs in colon cancer chemoprevention.

"It might seem strange that nitric oxide delivery could benefit both the brain and colon," Thatcher said. But nitric oxide bound to aspirin -- or nitro-aspirin -- was in clinical trials for colon cancer chemoprevention before the trial was stopped for safety concerns, he said.

"Our brain-targeted nitric oxide chimera drugs were the first to be studied in humans, and although we did not pioneer the nitric oxide related drugs for colon cancer, we believe that they hold promise."

Dr. Richard Benya and Dr. Robert Carroll in the department of medicine at UIC are assisting Thatcher in the colon cancer research project.

"There have been no significant advances in the survival of patients with colon cancer since President Richard Nixon declared the war on cancer in 1971," Benya said. "We desperately need new drugs, not only to treat this type of tumor, but to prevent it as well."

Source: University of Illinois at Chicago

Explore further: Haiti cholera outbreak kills 132 in 2014

add to favorites email to friend print save as pdf

Related Stories

New 2-D quantum materials for nanoelectronics

6 minutes ago

Researchers at MIT say they have carried out a theoretical analysis showing that a family of two-dimensional materials exhibits exotic quantum properties that may enable a new type of nanoscale electronics.

Researchers explore future of 'postdigital' textbook

12 minutes ago

An interdisciplinary team at Arizona State University has been awarded a grant from the National Science Foundation's Cyberlearning and Future Learning Technologies program to conduct research on the future ...

How to keep the world's eyes out of your webcam

33 minutes ago

There are concerns that thousands of private webcams around the world could be streaming live images to anybody who wishes to view them – without their owner knowing – thanks to a Russian website provi ...

Recommended for you

Ebola vaccine promising in first human trials

6 hours ago

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

9 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

EU calls for 5,000 doctors to fight Ebola

9 hours ago

The European Commission called for 5,000 doctors to be sent from EU states to combat west Africa's Ebola epidemic, a European source with knowledge of the matter said on Wednesday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.